Skip to main content
. 2016 Jun 10;6:27912. doi: 10.1038/srep27912

Figure 3. Inflammasome inhibition with MCC950 provides protection and reduces inflammation against IAV-induced pathogenicity.

Figure 3

C57BL/6 mice (n = 5 mice/group) were intranasally infected with 50 PFU of PR8 and treated with MCC950 (5mg/kg) on (a/c) days 1, 3, 5, 7 or (b/d) day 7 and 9 (arrows). (a/b) Survival curves are shown. ***p < 0.001, Mantel–Cox log-rank test and represent 2 independent experiments. (c/d) Mice were weighed daily and resulted expressed as mean percent weight change. (e–l) Wild type C57Bl/6 mice (n = 5/group) were intranasally inoculated with PR8 (50 PFU) alone or in combination with MCC950 (5 mg/kg) on day 7 post-infection and euthanized 24 h later. (e–h) Total numbers of leukocytes in BAL were determined by viable cell counts and numbers of Ly6G+ neutrophils and Ly6C+ inflammatory macrophages in BAL were determined by flow cytometry. (I–k) Levels of pro-inflammatory cytokines were determined by ELISA or CBA in BAL fluid. Data presented is mean ± SEM from 5 mice per group of 2 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA. (l) Viral loads in the lung and nasal tissues by standard plaque assay.